spg601
Small moleculeexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 5, 2024 (NCT06413537)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06413537 | Phase 2 | Jul 5, 2024 | Avance Clinical Pty Ltd., Spinogenix, University of Cincinnati |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Avance Clinical Pty Ltd. | For profit | 1 | 0 | 1 | 2024 |
| Spinogenix | For profit | 1 | 1 | 1 | 2024 |
| University of Cincinnati | Academic/Hospital | 1 | 0 | 1 | 2024 |
3 organizations
Page 1 / 1